AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Policy

Biopharma Update on the Novel Coronavirus: September 11

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.

September 10, 2020

2 min read

BioSpace Editorial Staff

Business

The Sky Remains the Limit for AbbVie with New Collaborative Partnerships

AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.

September 4, 2020

3 min read

Krystle Vermes

Policy

House Committee Subpoenas AbbVie Over Drug Pricing for Humira, Imbruvica

Shares of AbbVie fell nearly 4% Tuesday following the issuance of a subpoena from the U.S. House Oversight and Reform Committee regarding an ongoing investigation into drug pricing.

September 2, 2020

3 min read

Alex Keown

Business

AbbVie Taps Harvard University for Viral Infection Research Partnership

AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.

August 25, 2020

2 min read

Alex Keown

Business

AbbVie Expands Fibrotic Disease Partnership With Morphic Therapeutics

Under terms of the licensing deal, Morphic will receive an infusion of $20 million for the license fee along with potential future development milestone payments and royalties from the sales of any commercialized candidates.

August 25, 2020

2 min read

Alex Keown

BioCapital

Clinical Catch-Up: August 3-7

It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

August 6, 2020

8 min read

Mark Terry